STOCK TITAN

Relay Therapeutics (RLAY) 10-Q Filings

RLAY NASDAQ

Here are the 10-Q quarterly reports from Relay Therapeutics, Inc. (RLAY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow RLAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLAY filings page.

Rhea-AI Summary

Relay Therapeutics, Inc. reported a third-quarter 2026 net loss of $81.745 million, compared with $74.149 million a year earlier; net loss per share was ($0.37) versus ($0.43). Research and development expense was $77.138 million, up from $68.262 million. For the first nine months, net loss was $238.743 million versus $221.589 million, while license and other revenue was $3.350 million versus $8.355 million.

Cash, cash equivalents and investments totaled $848.6 million as of September 30, 2026. Relay expects those resources to fund operating expenses and capital expenditures into 2029, based on assumptions that may prove wrong. Net cash used in operations for the nine months was $169.155 million, compared with $190.590 million. In May 2026, Relay completed a public offering of 26,354,167 common shares at $12.00 per share, receiving $296.8 million net.

The FDA granted full approval in September 2026 for LYRFIGTU (lirafugratinib), as a treatment option for cholangiocarcinoma with FGFR2 fusion or other rearrangement. Elevar was granted exclusive global development and commercialization rights; Relay is eligible for up to $485.0 million in regulatory and commercial milestone payments plus tiered royalties. Relay initiated a Phase 3 registrational study of zovegalisib plus fulvestrant in advanced breast cancer.

Rhea-AI Summary

Relay Therapeutics (RLAY) filed its Q3 2025 report, highlighting continued R&D progress and a stronger balance sheet cushion. The company reported a net loss of $74.1M for the quarter versus $88.1M a year ago, as operating expenses declined with research and development at $68.3M and general and administrative at $12.1M. Quarterly revenue was $0; year-to-date revenue was $8.4M, primarily from the Elevar agreement tied to lirafugratinib.

Cash and investments totaled $596.4M ($91.6M cash and equivalents; $504.9M investments) at September 30, 2025, and management states this can fund operations into 2029. Shares outstanding were 173,322,385 as of October 31, 2025. The Genentech collaboration for migoprotafib ended effective January 7, 2025. Relay advanced RLY‑2608, initiating the global Phase 3 ReDiscover‑2 trial in HR+/HER2‑ breast cancer and reported interim PFS signals in combination with fulvestrant. Lease actions reduced footprint, including a terminated 399 Binney lease and a new, smaller One Kendall Square office lease.